Primary Immunodeficiency
35
4
4
22
Key Insights
Highlights
Success Rate
92% trial completion (above average)
Published Results
13 trials with published results (37%)
Clinical Risk Assessment
Based on trial outcomes
Low Risk
Score: 17/100
5.7%
2 terminated out of 35 trials
91.7%
+5.1% vs benchmark
46%
16 trials in Phase 3/4
59%
13 of 22 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.6%
Based on 22 completed trials
Clinical Trials (35)
Send-In Sample Collection to Achieve Genetic and Immunologic Characterization of Primary Immunodeficiencies
NIAID Centralized Sequencing Protocol
Metabolic Profiling of Immune Responses in Immune-mediated Diseases
Establishing Fibroblast-Derived Cell Lines From Skin Biopsies of Patients With Immunodeficiency or Immunodysregulation Disorders
Conception of a Diagnosis, Prognosis and Therapeutic Decision Tool for Patients With Autoimmunity and Inflammation
An Open-label, Multicenter Study to Assess the Pharmacokinetics (PK), Safety, and Tolerability of Subcutaneous IgPro20 in Immunoglobulin (IG) Treatment-naïve Participants With Primary Immunodeficiency (PID)
Bronchiectasis Prevalence in Patients With Primary Humoral Immunodefiency in Champagne-Ardenne Region, France
Quality of Life Among Children With Inborn Error of Immunity
Severe Immune Cytopenia Registry Www.Sic-reg.Org
Bilateral Orthotopic Lung Transplant - Bone Marrow Transplant
Investigation of the Effects of Pulmonary Rehabilitation in Children With Primary Immunodeficiency
A Study to Evaluate IGSC 20% Biweekly Dosing in Treatment-Experienced Participants and Loading/Maintenance Dosing in Treatment-Naïve Participants With Primary Immunodeficiency
Safety Study of Gene Modified Donor T-cells Following TCRαβ+ Depleted Stem Cell Transplant
Long Term Follow-up Study for Patients Enrolled on the BP-004 Clinical Study
Facilitated Immunoglobulin Administration Registry and Outcomes Study (FIGARO)
A Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Immune Globulin (Human) 10% (Gamunex-C) PEG Process (IVIG-PEG) Compared to Gamunex-C in Participants With Primary Humoral Immunodeficiency
What is the Incidence of an Immune Disorder in Children With Invasive Pneumococcal Disease (IPD)?
Study of ProMetic BioTherapeutics Immune Globulin Intravenous (Human) 10%
Systematic Screening for Primary Immunodeficiencies in Patients Hospitalized for Severe Infections in Intensive Care.
Efficacy and Safety Study of Kedrion IVIG 10% to Treat Subjects With Primary Immunodeficiency (PID)